To improve outcomes for women with advanced serous ovarian cancer it would be very helpful to have a therapeutic intervention that would increase the response to primary therapy, much as Herceptin does in women with Her2/neu positive breast cancer. Needed would be the novel therapeutic agent itself, and a means of identifying the women most likely to benefit from it. A way to identify the women least likely to achieve a complete response to standard therapy would be a first step in this direction. If successful, a product of the proposed work will be a molecular prognostic classifier validated for potential use in a Phase I trial. It will predict failure to respond to standard therapy by disease progression or persistence vs. a disease free interval of at least 20 months. In addition, as a result of the proposed work, therapeutic targets will have been identified for future development and testing in Phase I trials. Well over half of newly diagnosed women with ovarian cancer will die of their disease, and the relative resistance to standard chemotherapeutic agents displayed by most ovarian cancers represents a significant clinical challenge. To characterize the molecular abnormalities in ovarian cancer and to determine how these might relate to the differences in biological behavior displayed by these tumors, we have utilized cDNA microarrays to identify specific genes that are differentially expressed in normal vs. malignant ovarian tissue as well as in therapy responsive vs. therapy non-responsive ovarian cancers. We propose to extend these studies to validate and refine a molecular prognostic classifier that will identify those women with advanced (stage Ill/IV) ovarian cancer who are unlikely to respond to standard therapy. We will also functionally characterize genes that are differentially expressed in therapy responsive vs. therapy non-responsive ovarian cancer, emphasizing the potential role of these genes in mediating the response of ovarian cancer cells to standard chemotherapeutic agents. Our overall goals are to develop better prognostic markers that will aid in the optimal treatment of women with late stage serous ovarian cancer, and to identify novel therapeutic targets involved in the chemoresistance of ovarian cancer, the primary cause of treatment failure and death in women presenting with advanced disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA083636-07
Application #
7100990
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
7
Fiscal Year
2005
Total Cost
$376,333
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Hooda, Jagmohan; Novak, Marian; Salomon, Matthew P et al. (2018) Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Res :
Kondrashova, Olga; Topp, Monique; Nesic, Ksenija et al. (2018) Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 9:3970
Kroeger Jr, Paul T; Drapkin, Ronny (2017) Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29:26-34
Yu-Rice, Yi; Edassery, Seby L; Urban, Nicole et al. (2017) Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer. Reproduction 153:277-284
Liao, John B; Swensen, Ron E; Ovenell, Kelsie J et al. (2017) Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol 144:480-485
Vragniau, Charles; Hübner, Jens-Martin; Beidler, Peter et al. (2017) Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol 91:
Kondrashova, Olga; Nguyen, Minh; Shield-Artin, Kristy et al. (2017) Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 7:984-998
Au-Yeung, George; Lang, Franziska; Azar, Walid J et al. (2017) Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res 23:1862-1874
Liu, Joyce F; Palakurthi, Sangeetha; Zeng, Qing et al. (2017) Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res 23:1263-1273
Zheng, Grace X Y; Terry, Jessica M; Belgrader, Phillip et al. (2017) Massively parallel digital transcriptional profiling of single cells. Nat Commun 8:14049

Showing the most recent 10 out of 187 publications